nodes	percent_of_prediction	percent_of_DWPC	metapath
Naloxone—CREB1—sarcoma	0.727	1	CbGaD
Naloxone—CYP3A4—Thiotepa—sarcoma	0.0213	0.178	CbGbCtD
Naloxone—ABCB1—Dactinomycin—sarcoma	0.0171	0.143	CbGbCtD
Naloxone—ABCB1—Mitoxantrone—sarcoma	0.0153	0.128	CbGbCtD
Naloxone—CYP2C8—Etoposide—sarcoma	0.0142	0.119	CbGbCtD
Naloxone—ABCB1—Vincristine—sarcoma	0.0105	0.0878	CbGbCtD
Naloxone—ABCB1—Etoposide—sarcoma	0.00963	0.0805	CbGbCtD
Naloxone—CYP3A4—Mitoxantrone—sarcoma	0.00915	0.0764	CbGbCtD
Naloxone—ABCB1—Doxorubicin—sarcoma	0.00657	0.0549	CbGbCtD
Naloxone—CYP3A4—Vincristine—sarcoma	0.0063	0.0526	CbGbCtD
Naloxone—CYP3A4—Etoposide—sarcoma	0.00577	0.0482	CbGbCtD
Naloxone—CYP3A4—Doxorubicin—sarcoma	0.00394	0.0329	CbGbCtD
Naloxone—ESR1—periosteum—sarcoma	0.00238	0.0722	CbGeAlD
Naloxone—CREB1—mammary gland—sarcoma	0.0018	0.0545	CbGeAlD
Naloxone—TLR4—tendon—sarcoma	0.00164	0.0499	CbGeAlD
Naloxone—TLR4—bone marrow—sarcoma	0.00159	0.0483	CbGeAlD
Naloxone—TLR4—testis—sarcoma	0.00136	0.0413	CbGeAlD
Naloxone—TLR4—liver—sarcoma	0.00129	0.0391	CbGeAlD
Naloxone—CREB1—myometrium—sarcoma	0.00127	0.0387	CbGeAlD
Naloxone—CREB1—embryo—sarcoma	0.00123	0.0372	CbGeAlD
Naloxone—CREB1—hematopoietic system—sarcoma	0.00109	0.0332	CbGeAlD
Naloxone—CREB1—connective tissue—sarcoma	0.00105	0.032	CbGeAlD
Naloxone—TLR4—lymph node—sarcoma	0.000987	0.0299	CbGeAlD
Naloxone—CREB1—smooth muscle tissue—sarcoma	0.000964	0.0292	CbGeAlD
Naloxone—CREB1—skin of body—sarcoma	0.000951	0.0289	CbGeAlD
Naloxone—Encephalopathy—Thiotepa—sarcoma	0.00084	0.0332	CcSEcCtD
Naloxone—ALB—mammary gland—sarcoma	0.000829	0.0251	CbGeAlD
Naloxone—CREB1—uterus—sarcoma	0.000826	0.0251	CbGeAlD
Naloxone—CREB1—lymphoid tissue—sarcoma	0.00077	0.0234	CbGeAlD
Naloxone—CREB1—tendon—sarcoma	0.000724	0.022	CbGeAlD
Naloxone—Abdominal cramps—Vincristine—sarcoma	0.000708	0.028	CcSEcCtD
Naloxone—ESR1—mammary gland—sarcoma	0.000707	0.0214	CbGeAlD
Naloxone—CREB1—bone marrow—sarcoma	0.000701	0.0213	CbGeAlD
Naloxone—CREB1—testis—sarcoma	0.0006	0.0182	CbGeAlD
Naloxone—OPRM1—hematopoietic system—sarcoma	0.00059	0.0179	CbGeAlD
Naloxone—CYP2C8—mammary gland—sarcoma	0.000582	0.0177	CbGeAlD
Naloxone—CREB1—liver—sarcoma	0.000567	0.0172	CbGeAlD
Naloxone—SLCO1A2—hematopoietic system—sarcoma	0.000508	0.0154	CbGeAlD
Naloxone—ESR1—myometrium—sarcoma	0.000502	0.0152	CbGeAlD
Naloxone—ESR1—embryo—sarcoma	0.000482	0.0146	CbGeAlD
Naloxone—Pulmonary oedema—Thiotepa—sarcoma	0.00048	0.0189	CcSEcCtD
Naloxone—Coma—Vincristine—sarcoma	0.000437	0.0172	CcSEcCtD
Naloxone—CREB1—lymph node—sarcoma	0.000435	0.0132	CbGeAlD
Naloxone—ESR1—hematopoietic system—sarcoma	0.000431	0.0131	CbGeAlD
Naloxone—ESR1—connective tissue—sarcoma	0.000415	0.0126	CbGeAlD
Naloxone—ESR1—smooth muscle tissue—sarcoma	0.000379	0.0115	CbGeAlD
Naloxone—Cardiac arrest—Thiotepa—sarcoma	0.000372	0.0147	CcSEcCtD
Naloxone—CYP2C8—hematopoietic system—sarcoma	0.000355	0.0108	CbGeAlD
Naloxone—Cardiac arrest—Vincristine—sarcoma	0.00033	0.013	CcSEcCtD
Naloxone—ESR1—uterus—sarcoma	0.000325	0.00987	CbGeAlD
Naloxone—OPRM1—testis—sarcoma	0.000323	0.00981	CbGeAlD
Naloxone—ESR1—lymphoid tissue—sarcoma	0.000303	0.0092	CbGeAlD
Naloxone—SLCO1A2—testis—sarcoma	0.000278	0.00844	CbGeAlD
Naloxone—ALB—testis—sarcoma	0.000277	0.00839	CbGeAlD
Naloxone—Hallucination—Thiotepa—sarcoma	0.000269	0.0106	CcSEcCtD
Naloxone—Cardiac arrest—Etoposide—sarcoma	0.000267	0.0106	CcSEcCtD
Naloxone—Depression—Vincristine—sarcoma	0.000267	0.0105	CcSEcCtD
Naloxone—SLCO1A2—liver—sarcoma	0.000263	0.00798	CbGeAlD
Naloxone—ALB—liver—sarcoma	0.000262	0.00793	CbGeAlD
Naloxone—Sweating—Vincristine—sarcoma	0.000256	0.0101	CcSEcCtD
Naloxone—Cardiac disorder—Thiotepa—sarcoma	0.000251	0.00992	CcSEcCtD
Naloxone—Sweating—Mitoxantrone—sarcoma	0.00025	0.00986	CcSEcCtD
Naloxone—Flushing—Dactinomycin—sarcoma	0.000249	0.00984	CcSEcCtD
Naloxone—Angiopathy—Thiotepa—sarcoma	0.000246	0.0097	CcSEcCtD
Naloxone—Mediastinal disorder—Thiotepa—sarcoma	0.000244	0.00963	CcSEcCtD
Naloxone—Chills—Thiotepa—sarcoma	0.000243	0.00959	CcSEcCtD
Naloxone—Chills—Dactinomycin—sarcoma	0.000241	0.00952	CcSEcCtD
Naloxone—CYP3A4—hematopoietic system—sarcoma	0.00024	0.00729	CbGeAlD
Naloxone—Hallucination—Vincristine—sarcoma	0.000239	0.00943	CcSEcCtD
Naloxone—Mental disorder—Thiotepa—sarcoma	0.000237	0.00936	CcSEcCtD
Naloxone—ESR1—testis—sarcoma	0.000236	0.00716	CbGeAlD
Naloxone—Tension—Thiotepa—sarcoma	0.000231	0.00913	CcSEcCtD
Naloxone—Nervousness—Thiotepa—sarcoma	0.000229	0.00904	CcSEcCtD
Naloxone—ESR1—liver—sarcoma	0.000223	0.00677	CbGeAlD
Naloxone—Cardiac disorder—Vincristine—sarcoma	0.000223	0.00879	CcSEcCtD
Naloxone—Angiopathy—Vincristine—sarcoma	0.000218	0.0086	CcSEcCtD
Naloxone—Ventricular tachycardia—Epirubicin—sarcoma	0.000217	0.00857	CcSEcCtD
Naloxone—Agitation—Thiotepa—sarcoma	0.000217	0.00855	CcSEcCtD
Naloxone—Mediastinal disorder—Vincristine—sarcoma	0.000216	0.00854	CcSEcCtD
Naloxone—Injection site reaction—Epirubicin—sarcoma	0.000216	0.00852	CcSEcCtD
Naloxone—Mental disorder—Vincristine—sarcoma	0.00021	0.0083	CcSEcCtD
Naloxone—Chills—Mitoxantrone—sarcoma	0.00021	0.00828	CcSEcCtD
Naloxone—Convulsion—Thiotepa—sarcoma	0.000204	0.00806	CcSEcCtD
Naloxone—Hypertension—Thiotepa—sarcoma	0.000204	0.00803	CcSEcCtD
Naloxone—Ventricular tachycardia—Doxorubicin—sarcoma	0.000201	0.00793	CcSEcCtD
Naloxone—ALB—lymph node—sarcoma	0.000201	0.00608	CbGeAlD
Naloxone—Injection site reaction—Doxorubicin—sarcoma	0.0002	0.00788	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—sarcoma	0.000199	0.00787	CcSEcCtD
Naloxone—Coma—Epirubicin—sarcoma	0.000198	0.00783	CcSEcCtD
Naloxone—ABCB1—myometrium—sarcoma	0.000198	0.00601	CbGeAlD
Naloxone—CYP2C8—testis—sarcoma	0.000194	0.0059	CbGeAlD
Naloxone—Pulmonary oedema—Epirubicin—sarcoma	0.000193	0.00763	CcSEcCtD
Naloxone—Agitation—Vincristine—sarcoma	0.000192	0.00758	CcSEcCtD
Naloxone—ABCB1—embryo—sarcoma	0.000191	0.00578	CbGeAlD
Naloxone—Nervous system disorder—Thiotepa—sarcoma	0.000189	0.00745	CcSEcCtD
Naloxone—Tachycardia—Thiotepa—sarcoma	0.000188	0.00741	CcSEcCtD
Naloxone—Skin disorder—Thiotepa—sarcoma	0.000187	0.00737	CcSEcCtD
Naloxone—CYP2C8—liver—sarcoma	0.000184	0.00558	CbGeAlD
Naloxone—Coma—Doxorubicin—sarcoma	0.000184	0.00724	CcSEcCtD
Naloxone—Convulsion—Vincristine—sarcoma	0.000181	0.00715	CcSEcCtD
Naloxone—Flushing—Etoposide—sarcoma	0.000181	0.00712	CcSEcCtD
Naloxone—Cardiac disorder—Etoposide—sarcoma	0.000181	0.00712	CcSEcCtD
Naloxone—Hypertension—Vincristine—sarcoma	0.00018	0.00712	CcSEcCtD
Naloxone—ABCB1—seminal vesicle—sarcoma	0.000179	0.00543	CbGeAlD
Naloxone—Pulmonary oedema—Doxorubicin—sarcoma	0.000179	0.00706	CcSEcCtD
Naloxone—Angiopathy—Etoposide—sarcoma	0.000176	0.00696	CcSEcCtD
Naloxone—Convulsion—Mitoxantrone—sarcoma	0.000176	0.00696	CcSEcCtD
Naloxone—Hypertension—Mitoxantrone—sarcoma	0.000176	0.00694	CcSEcCtD
Naloxone—Mediastinal disorder—Etoposide—sarcoma	0.000175	0.00692	CcSEcCtD
Naloxone—Chills—Etoposide—sarcoma	0.000175	0.00689	CcSEcCtD
Naloxone—Paraesthesia—Thiotepa—sarcoma	0.000173	0.00682	CcSEcCtD
Naloxone—ESR1—lymph node—sarcoma	0.000171	0.00519	CbGeAlD
Naloxone—ABCB1—hematopoietic system—sarcoma	0.00017	0.00516	CbGeAlD
Naloxone—Hot flush—Epirubicin—sarcoma	0.000168	0.00665	CcSEcCtD
Naloxone—Nervous system disorder—Vincristine—sarcoma	0.000167	0.0066	CcSEcCtD
Naloxone—Menopausal symptoms—Epirubicin—sarcoma	0.000167	0.00659	CcSEcCtD
Naloxone—Gastrointestinal disorder—Thiotepa—sarcoma	0.000166	0.00655	CcSEcCtD
Naloxone—Hyperhidrosis—Vincristine—sarcoma	0.000165	0.00651	CcSEcCtD
Naloxone—Pain—Thiotepa—sarcoma	0.000165	0.00649	CcSEcCtD
Naloxone—Pain—Dactinomycin—sarcoma	0.000163	0.00644	CcSEcCtD
Naloxone—Tachycardia—Mitoxantrone—sarcoma	0.000162	0.0064	CcSEcCtD
Naloxone—Skin disorder—Mitoxantrone—sarcoma	0.000161	0.00637	CcSEcCtD
Naloxone—Hyperhidrosis—Mitoxantrone—sarcoma	0.000161	0.00634	CcSEcCtD
Naloxone—Hot flush—Doxorubicin—sarcoma	0.000156	0.00615	CcSEcCtD
Naloxone—Menopausal symptoms—Doxorubicin—sarcoma	0.000155	0.0061	CcSEcCtD
Naloxone—Paraesthesia—Vincristine—sarcoma	0.000153	0.00605	CcSEcCtD
Naloxone—Abdominal pain—Thiotepa—sarcoma	0.000152	0.006	CcSEcCtD
Naloxone—Body temperature increased—Thiotepa—sarcoma	0.000152	0.006	CcSEcCtD
Naloxone—Abdominal pain—Dactinomycin—sarcoma	0.000151	0.00596	CcSEcCtD
Naloxone—Body temperature increased—Dactinomycin—sarcoma	0.000151	0.00596	CcSEcCtD
Naloxone—Cardiac arrest—Epirubicin—sarcoma	0.00015	0.00591	CcSEcCtD
Naloxone—Paraesthesia—Mitoxantrone—sarcoma	0.000149	0.00589	CcSEcCtD
Naloxone—Dyspnoea—Mitoxantrone—sarcoma	0.000148	0.00585	CcSEcCtD
Naloxone—Gastrointestinal disorder—Vincristine—sarcoma	0.000147	0.00581	CcSEcCtD
Naloxone—Convulsion—Etoposide—sarcoma	0.000147	0.00579	CcSEcCtD
Naloxone—Hypertension—Etoposide—sarcoma	0.000146	0.00577	CcSEcCtD
Naloxone—Pain—Vincristine—sarcoma	0.000146	0.00576	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.000143	0.00565	CcSEcCtD
Naloxone—Pain—Mitoxantrone—sarcoma	0.000142	0.00561	CcSEcCtD
Naloxone—Nasopharyngitis—Epirubicin—sarcoma	0.000141	0.00556	CcSEcCtD
Naloxone—Cardiac arrest—Doxorubicin—sarcoma	0.000139	0.00547	CcSEcCtD
Naloxone—Asthenia—Thiotepa—sarcoma	0.000138	0.00545	CcSEcCtD
Naloxone—Asthenia—Dactinomycin—sarcoma	0.000137	0.00541	CcSEcCtD
Naloxone—Tachycardia—Etoposide—sarcoma	0.000135	0.00532	CcSEcCtD
Naloxone—Body temperature increased—Vincristine—sarcoma	0.000135	0.00532	CcSEcCtD
Naloxone—Abdominal pain—Vincristine—sarcoma	0.000135	0.00532	CcSEcCtD
Naloxone—Skin disorder—Etoposide—sarcoma	0.000134	0.0053	CcSEcCtD
Naloxone—Hyperhidrosis—Etoposide—sarcoma	0.000134	0.00527	CcSEcCtD
Naloxone—Diarrhoea—Thiotepa—sarcoma	0.000132	0.00519	CcSEcCtD
Naloxone—Body temperature increased—Mitoxantrone—sarcoma	0.000131	0.00518	CcSEcCtD
Naloxone—Abdominal pain—Mitoxantrone—sarcoma	0.000131	0.00518	CcSEcCtD
Naloxone—Diarrhoea—Dactinomycin—sarcoma	0.000131	0.00516	CcSEcCtD
Naloxone—Nasopharyngitis—Doxorubicin—sarcoma	0.00013	0.00515	CcSEcCtD
Naloxone—ABCB1—uterus—sarcoma	0.000128	0.0039	CbGeAlD
Naloxone—CYP3A4—liver—sarcoma	0.000125	0.00378	CbGeAlD
Naloxone—Paraesthesia—Etoposide—sarcoma	0.000124	0.0049	CcSEcCtD
Naloxone—Dyspnoea—Etoposide—sarcoma	0.000123	0.00486	CcSEcCtD
Naloxone—Asthenia—Vincristine—sarcoma	0.000122	0.00483	CcSEcCtD
Naloxone—Vomiting—Thiotepa—sarcoma	0.000122	0.00483	CcSEcCtD
Naloxone—Vomiting—Dactinomycin—sarcoma	0.000121	0.00479	CcSEcCtD
Naloxone—ABCB1—lymphoid tissue—sarcoma	0.00012	0.00363	CbGeAlD
Naloxone—Gastrointestinal disorder—Etoposide—sarcoma	0.000119	0.00471	CcSEcCtD
Naloxone—Asthenia—Mitoxantrone—sarcoma	0.000119	0.0047	CcSEcCtD
Naloxone—Pain—Etoposide—sarcoma	0.000118	0.00466	CcSEcCtD
Naloxone—Diarrhoea—Vincristine—sarcoma	0.000117	0.00461	CcSEcCtD
Naloxone—Sweating—Epirubicin—sarcoma	0.000116	0.0046	CcSEcCtD
Naloxone—Nausea—Thiotepa—sarcoma	0.000114	0.00451	CcSEcCtD
Naloxone—Diarrhoea—Mitoxantrone—sarcoma	0.000114	0.00449	CcSEcCtD
Naloxone—Nausea—Dactinomycin—sarcoma	0.000113	0.00448	CcSEcCtD
Naloxone—Abdominal pain—Etoposide—sarcoma	0.000109	0.00431	CcSEcCtD
Naloxone—Body temperature increased—Etoposide—sarcoma	0.000109	0.00431	CcSEcCtD
Naloxone—ABCB1—bone marrow—sarcoma	0.000109	0.00331	CbGeAlD
Naloxone—Vomiting—Vincristine—sarcoma	0.000108	0.00428	CcSEcCtD
Naloxone—Sweating—Doxorubicin—sarcoma	0.000108	0.00425	CcSEcCtD
Naloxone—Vomiting—Mitoxantrone—sarcoma	0.000106	0.00417	CcSEcCtD
Naloxone—Nausea—Vincristine—sarcoma	0.000101	0.004	CcSEcCtD
Naloxone—Flushing—Epirubicin—sarcoma	0.000101	0.00399	CcSEcCtD
Naloxone—Cardiac disorder—Epirubicin—sarcoma	0.000101	0.00399	CcSEcCtD
Naloxone—Asthenia—Etoposide—sarcoma	9.91e-05	0.00391	CcSEcCtD
Naloxone—Angiopathy—Epirubicin—sarcoma	9.89e-05	0.0039	CcSEcCtD
Naloxone—Nausea—Mitoxantrone—sarcoma	9.87e-05	0.00389	CcSEcCtD
Naloxone—Mediastinal disorder—Epirubicin—sarcoma	9.83e-05	0.00388	CcSEcCtD
Naloxone—Chills—Epirubicin—sarcoma	9.78e-05	0.00386	CcSEcCtD
Naloxone—Mental disorder—Epirubicin—sarcoma	9.55e-05	0.00377	CcSEcCtD
Naloxone—Diarrhoea—Etoposide—sarcoma	9.45e-05	0.00373	CcSEcCtD
Naloxone—Flushing—Doxorubicin—sarcoma	9.36e-05	0.0037	CcSEcCtD
Naloxone—Cardiac disorder—Doxorubicin—sarcoma	9.36e-05	0.0037	CcSEcCtD
Naloxone—ABCB1—testis—sarcoma	9.32e-05	0.00283	CbGeAlD
Naloxone—Tension—Epirubicin—sarcoma	9.31e-05	0.00368	CcSEcCtD
Naloxone—Nervousness—Epirubicin—sarcoma	9.22e-05	0.00364	CcSEcCtD
Naloxone—Angiopathy—Doxorubicin—sarcoma	9.15e-05	0.00361	CcSEcCtD
Naloxone—Mediastinal disorder—Doxorubicin—sarcoma	9.09e-05	0.00359	CcSEcCtD
Naloxone—Chills—Doxorubicin—sarcoma	9.05e-05	0.00357	CcSEcCtD
Naloxone—Mental disorder—Doxorubicin—sarcoma	8.84e-05	0.00349	CcSEcCtD
Naloxone—ABCB1—liver—sarcoma	8.81e-05	0.00267	CbGeAlD
Naloxone—Vomiting—Etoposide—sarcoma	8.79e-05	0.00347	CcSEcCtD
Naloxone—Agitation—Epirubicin—sarcoma	8.72e-05	0.00344	CcSEcCtD
Naloxone—Tension—Doxorubicin—sarcoma	8.62e-05	0.0034	CcSEcCtD
Naloxone—Nervousness—Doxorubicin—sarcoma	8.53e-05	0.00337	CcSEcCtD
Naloxone—Convulsion—Epirubicin—sarcoma	8.22e-05	0.00325	CcSEcCtD
Naloxone—Nausea—Etoposide—sarcoma	8.21e-05	0.00324	CcSEcCtD
Naloxone—Hypertension—Epirubicin—sarcoma	8.19e-05	0.00323	CcSEcCtD
Naloxone—Agitation—Doxorubicin—sarcoma	8.07e-05	0.00319	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	8.02e-05	0.00317	CcSEcCtD
Naloxone—Convulsion—Doxorubicin—sarcoma	7.61e-05	0.003	CcSEcCtD
Naloxone—Nervous system disorder—Epirubicin—sarcoma	7.6e-05	0.003	CcSEcCtD
Naloxone—Hypertension—Doxorubicin—sarcoma	7.58e-05	0.00299	CcSEcCtD
Naloxone—Tachycardia—Epirubicin—sarcoma	7.56e-05	0.00298	CcSEcCtD
Naloxone—Skin disorder—Epirubicin—sarcoma	7.52e-05	0.00297	CcSEcCtD
Naloxone—Hyperhidrosis—Epirubicin—sarcoma	7.49e-05	0.00296	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	7.42e-05	0.00293	CcSEcCtD
Naloxone—Nervous system disorder—Doxorubicin—sarcoma	7.03e-05	0.00277	CcSEcCtD
Naloxone—Tachycardia—Doxorubicin—sarcoma	6.99e-05	0.00276	CcSEcCtD
Naloxone—Skin disorder—Doxorubicin—sarcoma	6.96e-05	0.00275	CcSEcCtD
Naloxone—Paraesthesia—Epirubicin—sarcoma	6.96e-05	0.00275	CcSEcCtD
Naloxone—Hyperhidrosis—Doxorubicin—sarcoma	6.93e-05	0.00273	CcSEcCtD
Naloxone—Dyspnoea—Epirubicin—sarcoma	6.91e-05	0.00273	CcSEcCtD
Naloxone—ABCB1—lymph node—sarcoma	6.76e-05	0.00205	CbGeAlD
Naloxone—Gastrointestinal disorder—Epirubicin—sarcoma	6.69e-05	0.00264	CcSEcCtD
Naloxone—Pain—Epirubicin—sarcoma	6.62e-05	0.00261	CcSEcCtD
Naloxone—Paraesthesia—Doxorubicin—sarcoma	6.44e-05	0.00254	CcSEcCtD
Naloxone—Dyspnoea—Doxorubicin—sarcoma	6.39e-05	0.00252	CcSEcCtD
Naloxone—Gastrointestinal disorder—Doxorubicin—sarcoma	6.19e-05	0.00244	CcSEcCtD
Naloxone—Pain—Doxorubicin—sarcoma	6.13e-05	0.00242	CcSEcCtD
Naloxone—Abdominal pain—Epirubicin—sarcoma	6.12e-05	0.00242	CcSEcCtD
Naloxone—Body temperature increased—Epirubicin—sarcoma	6.12e-05	0.00242	CcSEcCtD
Naloxone—Abdominal pain—Doxorubicin—sarcoma	5.67e-05	0.00224	CcSEcCtD
Naloxone—Body temperature increased—Doxorubicin—sarcoma	5.67e-05	0.00224	CcSEcCtD
Naloxone—Asthenia—Epirubicin—sarcoma	5.56e-05	0.00219	CcSEcCtD
Naloxone—Diarrhoea—Epirubicin—sarcoma	5.3e-05	0.00209	CcSEcCtD
Naloxone—Asthenia—Doxorubicin—sarcoma	5.14e-05	0.00203	CcSEcCtD
Naloxone—Vomiting—Epirubicin—sarcoma	4.92e-05	0.00194	CcSEcCtD
Naloxone—Diarrhoea—Doxorubicin—sarcoma	4.9e-05	0.00194	CcSEcCtD
Naloxone—Nausea—Epirubicin—sarcoma	4.6e-05	0.00182	CcSEcCtD
Naloxone—Vomiting—Doxorubicin—sarcoma	4.56e-05	0.0018	CcSEcCtD
Naloxone—Nausea—Doxorubicin—sarcoma	4.26e-05	0.00168	CcSEcCtD
Naloxone—OPRD1—Signaling Pathways—VEGFC—sarcoma	2.75e-05	0.00029	CbGpPWpGaD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	2.72e-05	0.000287	CbGpPWpGaD
Naloxone—ESR1—Integrated Breast Cancer Pathway—TP53—sarcoma	2.7e-05	0.000284	CbGpPWpGaD
Naloxone—CREB1—Axon guidance—EGFR—sarcoma	2.66e-05	0.000281	CbGpPWpGaD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	2.66e-05	0.000281	CbGpPWpGaD
Naloxone—TLR4—Immune System—KRAS—sarcoma	2.64e-05	0.000279	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—CXCR4—sarcoma	2.61e-05	0.000275	CbGpPWpGaD
Naloxone—ESR1—Signaling by ERBB4—HRAS—sarcoma	2.56e-05	0.00027	CbGpPWpGaD
Naloxone—ALB—Hemostasis—PLCG1—sarcoma	2.53e-05	0.000267	CbGpPWpGaD
Naloxone—CREB1—Axon guidance—KRAS—sarcoma	2.51e-05	0.000265	CbGpPWpGaD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	2.51e-05	0.000265	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	2.49e-05	0.000263	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—ENO2—sarcoma	2.48e-05	0.000261	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—HBA1—sarcoma	2.46e-05	0.00026	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—MDM2—sarcoma	2.45e-05	0.000259	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—TLE1—sarcoma	2.42e-05	0.000255	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—VEGFC—sarcoma	2.41e-05	0.000255	CbGpPWpGaD
Naloxone—CREB1—Neuronal System—HRAS—sarcoma	2.41e-05	0.000254	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—CTNNB1—sarcoma	2.4e-05	0.000253	CbGpPWpGaD
Naloxone—CREB1—Immune System—FOXO1—sarcoma	2.38e-05	0.000251	CbGpPWpGaD
Naloxone—CREB1—Immune System—PDGFRB—sarcoma	2.38e-05	0.000251	CbGpPWpGaD
Naloxone—CREB1—Signaling by NGF—HRAS—sarcoma	2.36e-05	0.000249	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—MDM2—sarcoma	2.36e-05	0.000249	CbGpPWpGaD
Naloxone—CREB1—Immune System—PDGFRA—sarcoma	2.34e-05	0.000247	CbGpPWpGaD
Naloxone—TLR4—Immune System—HRAS—sarcoma	2.25e-05	0.000237	CbGpPWpGaD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	2.23e-05	0.000236	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—FLT1—sarcoma	2.21e-05	0.000233	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—FLT1—sarcoma	2.2e-05	0.000232	CbGpPWpGaD
Naloxone—CREB1—Disease—FOXO1—sarcoma	2.2e-05	0.000232	CbGpPWpGaD
Naloxone—CREB1—Disease—PDGFRB—sarcoma	2.2e-05	0.000232	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—PLCG1—sarcoma	2.17e-05	0.000229	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—SRC—sarcoma	2.17e-05	0.000229	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—PLCG1—sarcoma	2.16e-05	0.000228	CbGpPWpGaD
Naloxone—CREB1—Disease—PDGFRA—sarcoma	2.16e-05	0.000228	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TLE1—sarcoma	2.14e-05	0.000226	CbGpPWpGaD
Naloxone—CREB1—Axon guidance—HRAS—sarcoma	2.14e-05	0.000225	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—JUN—sarcoma	2.13e-05	0.000225	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—CTNNB1—sarcoma	2.12e-05	0.000223	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—VEGFA—sarcoma	2.11e-05	0.000223	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—PLCG1—sarcoma	2.1e-05	0.000222	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CXCR4—sarcoma	2.09e-05	0.00022	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—NRAS—sarcoma	2.08e-05	0.00022	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CXCR4—sarcoma	2.08e-05	0.000219	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—ATF1—sarcoma	2.06e-05	0.000217	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	2.06e-05	0.000217	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—ATF1—sarcoma	2.06e-05	0.000217	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—VEGFC—sarcoma	2.04e-05	0.000215	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—FLT1—sarcoma	1.93e-05	0.000204	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—SRC—sarcoma	1.91e-05	0.000202	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—EGFR—sarcoma	1.9e-05	0.0002	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—PLCG1—sarcoma	1.9e-05	0.0002	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—CREB1—sarcoma	1.89e-05	0.000199	CbGpPWpGaD
Naloxone—ALB—Platelet activation, signaling and aggregation—IL2—sarcoma	1.87e-05	0.000197	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—NRAS—sarcoma	1.84e-05	0.000194	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—SRC—sarcoma	1.84e-05	0.000194	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CXCR4—sarcoma	1.82e-05	0.000192	CbGpPWpGaD
Naloxone—CREB1—Immune System—KIT—sarcoma	1.82e-05	0.000191	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—VEGFC—sarcoma	1.81e-05	0.000191	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—ATF1—sarcoma	1.8e-05	0.00019	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	1.79e-05	0.000189	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—KRAS—sarcoma	1.79e-05	0.000189	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	1.79e-05	0.000189	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	1.78e-05	0.000187	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—NRAS—sarcoma	1.77e-05	0.000186	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—EGFR—sarcoma	1.68e-05	0.000177	CbGpPWpGaD
Naloxone—CREB1—Disease—KIT—sarcoma	1.68e-05	0.000177	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—CREB1—sarcoma	1.65e-05	0.000174	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—FLT1—sarcoma	1.63e-05	0.000172	CbGpPWpGaD
Naloxone—ALB—Platelet activation, signaling and aggregation—SRC—sarcoma	1.63e-05	0.000172	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—IGF1R—sarcoma	1.62e-05	0.000171	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—IGF1R—sarcoma	1.61e-05	0.00017	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—EGFR—sarcoma	1.61e-05	0.00017	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	1.61e-05	0.000169	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PLCG1—sarcoma	1.6e-05	0.000169	CbGpPWpGaD
Naloxone—ALB—Platelet activation, signaling and aggregation—VEGFA—sarcoma	1.59e-05	0.000168	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—KRAS—sarcoma	1.58e-05	0.000167	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	1.56e-05	0.000165	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CXCR4—sarcoma	1.54e-05	0.000162	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—FOXO1—sarcoma	1.54e-05	0.000162	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—PDGFRB—sarcoma	1.54e-05	0.000162	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—FOXO1—sarcoma	1.54e-05	0.000162	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—IL2—sarcoma	1.53e-05	0.000162	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—PDGFRB—sarcoma	1.53e-05	0.000162	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—HRAS—sarcoma	1.53e-05	0.000161	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—ATF1—sarcoma	1.52e-05	0.000161	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—KRAS—sarcoma	1.52e-05	0.00016	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—PDGFRA—sarcoma	1.51e-05	0.00016	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—PDGFRA—sarcoma	1.51e-05	0.000159	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—FLT1—sarcoma	1.45e-05	0.000153	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	1.44e-05	0.000152	CbGpPWpGaD
Naloxone—CREB1—Immune System—MDM2—sarcoma	1.43e-05	0.000151	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PLCG1—sarcoma	1.42e-05	0.00015	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—IGF1R—sarcoma	1.41e-05	0.000149	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	1.41e-05	0.000148	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—IL2—sarcoma	1.4e-05	0.000147	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—CREB1—sarcoma	1.4e-05	0.000147	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—IL2—sarcoma	1.39e-05	0.000147	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CXCR4—sarcoma	1.37e-05	0.000144	CbGpPWpGaD
Naloxone—ESR1—Generic Transcription Pathway—MYC—sarcoma	1.35e-05	0.000143	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—ATF1—sarcoma	1.35e-05	0.000142	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—HRAS—sarcoma	1.35e-05	0.000142	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—FOXO1—sarcoma	1.35e-05	0.000142	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—IL2—sarcoma	1.35e-05	0.000142	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—PDGFRB—sarcoma	1.34e-05	0.000142	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	1.33e-05	0.00014	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—PDGFRA—sarcoma	1.32e-05	0.00014	CbGpPWpGaD
Naloxone—CREB1—Disease—MDM2—sarcoma	1.32e-05	0.000139	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—HRAS—sarcoma	1.29e-05	0.000136	CbGpPWpGaD
Naloxone—CREB1—Immune System—IL2—sarcoma	1.28e-05	0.000135	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—KDR—sarcoma	1.27e-05	0.000134	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—KDR—sarcoma	1.27e-05	0.000134	CbGpPWpGaD
Naloxone—CREB1—Immune System—JUN—sarcoma	1.24e-05	0.000131	CbGpPWpGaD
Naloxone—CREB1—Immune System—CTNNB1—sarcoma	1.23e-05	0.00013	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—IL2—sarcoma	1.22e-05	0.000129	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—ENO2—sarcoma	1.22e-05	0.000128	CbGpPWpGaD
Naloxone—ALB—Metabolism—ENO2—sarcoma	1.21e-05	0.000128	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—HBA1—sarcoma	1.21e-05	0.000128	CbGpPWpGaD
Naloxone—ALB—Metabolism—HBA1—sarcoma	1.2e-05	0.000127	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IGF1R—sarcoma	1.2e-05	0.000126	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	1.18e-05	0.000125	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—KIT—sarcoma	1.17e-05	0.000124	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—NRAS—sarcoma	1.17e-05	0.000124	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—KIT—sarcoma	1.17e-05	0.000123	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—NRAS—sarcoma	1.17e-05	0.000123	CbGpPWpGaD
Naloxone—CREB1—Disease—CTNNB1—sarcoma	1.14e-05	0.00012	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—FOXO1—sarcoma	1.14e-05	0.00012	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—IL2—sarcoma	1.14e-05	0.00012	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PDGFRB—sarcoma	1.14e-05	0.00012	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PDGFRA—sarcoma	1.12e-05	0.000118	CbGpPWpGaD
Naloxone—CREB1—Immune System—SRC—sarcoma	1.11e-05	0.000118	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—KDR—sarcoma	1.11e-05	0.000117	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CREB1—sarcoma	1.11e-05	0.000117	CbGpPWpGaD
Naloxone—CREB1—Immune System—NRAS—sarcoma	1.07e-05	0.000113	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—EGFR—sarcoma	1.07e-05	0.000113	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—EGFR—sarcoma	1.07e-05	0.000112	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—ENO2—sarcoma	1.06e-05	0.000112	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IGF1R—sarcoma	1.06e-05	0.000112	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—HBA1—sarcoma	1.05e-05	0.000111	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—IL2—sarcoma	1.03e-05	0.000109	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PLCG1—sarcoma	1.03e-05	0.000109	CbGpPWpGaD
Naloxone—CREB1—Disease—SRC—sarcoma	1.03e-05	0.000109	CbGpPWpGaD
Naloxone—ALB—Metabolism—PLCG1—sarcoma	1.03e-05	0.000108	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—KIT—sarcoma	1.03e-05	0.000108	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—NRAS—sarcoma	1.03e-05	0.000108	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—KRAS—sarcoma	1.01e-05	0.000107	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—FOXO1—sarcoma	1.01e-05	0.000106	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PDGFRB—sarcoma	1.01e-05	0.000106	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—KRAS—sarcoma	1.01e-05	0.000106	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PDGFRA—sarcoma	9.91e-06	0.000105	CbGpPWpGaD
Naloxone—CREB1—Disease—NRAS—sarcoma	9.9e-06	0.000104	CbGpPWpGaD
Naloxone—CREB1—Immune System—EGFR—sarcoma	9.77e-06	0.000103	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CREB1—sarcoma	9.76e-06	0.000103	CbGpPWpGaD
Naloxone—ALB—Hemostasis—IL2—sarcoma	9.64e-06	0.000102	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—KDR—sarcoma	9.41e-06	9.93e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—EGFR—sarcoma	9.35e-06	9.86e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—MDM2—sarcoma	9.24e-06	9.75e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—KRAS—sarcoma	9.23e-06	9.73e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—MYC—sarcoma	9.22e-06	9.73e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—MDM2—sarcoma	9.21e-06	9.72e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—EGFR—sarcoma	9.02e-06	9.51e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PLCG1—sarcoma	9e-06	9.49e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—KRAS—sarcoma	8.83e-06	9.31e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—KIT—sarcoma	8.67e-06	9.14e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—NRAS—sarcoma	8.67e-06	9.14e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—HRAS—sarcoma	8.59e-06	9.06e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—HRAS—sarcoma	8.56e-06	9.03e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—KRAS—sarcoma	8.52e-06	8.99e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—SRC—sarcoma	8.41e-06	8.87e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—KDR—sarcoma	8.34e-06	8.8e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—IL2—sarcoma	8.26e-06	8.71e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CREB1—sarcoma	8.25e-06	8.7e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—IL2—sarcoma	8.23e-06	8.68e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—VEGFA—sarcoma	8.19e-06	8.64e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—NRAS—sarcoma	8.09e-06	8.53e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MDM2—sarcoma	8.08e-06	8.52e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CCND1—sarcoma	8.05e-06	8.49e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—JUN—sarcoma	8.03e-06	8.47e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CCND1—sarcoma	8.03e-06	8.46e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—JUN—sarcoma	8.01e-06	8.45e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CTNNB1—sarcoma	7.97e-06	8.41e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CTNNB1—sarcoma	7.95e-06	8.38e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—EGFR—sarcoma	7.9e-06	8.33e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—HRAS—sarcoma	7.84e-06	8.27e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—KIT—sarcoma	7.69e-06	8.11e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—HRAS—sarcoma	7.5e-06	7.91e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—KRAS—sarcoma	7.46e-06	7.87e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CREB1—sarcoma	7.32e-06	7.72e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—HRAS—sarcoma	7.24e-06	7.64e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—IL2—sarcoma	7.22e-06	7.61e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—SRC—sarcoma	7.21e-06	7.6e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—SRC—sarcoma	7.18e-06	7.58e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CCND1—sarcoma	7.04e-06	7.42e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—JUN—sarcoma	7.02e-06	7.41e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—VEGFA—sarcoma	7.02e-06	7.4e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—VEGFA—sarcoma	7e-06	7.38e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CTNNB1—sarcoma	6.97e-06	7.35e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—KRAS—sarcoma	6.96e-06	7.34e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—NRAS—sarcoma	6.93e-06	7.31e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—NRAS—sarcoma	6.91e-06	7.29e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MDM2—sarcoma	6.83e-06	7.2e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ENO2—sarcoma	6.53e-06	6.89e-05	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—MYC—sarcoma	6.51e-06	6.86e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—HBA1—sarcoma	6.49e-06	6.85e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—MYC—sarcoma	6.46e-06	6.81e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—MYC—sarcoma	6.44e-06	6.79e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—HRAS—sarcoma	6.34e-06	6.69e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—EGFR—sarcoma	6.32e-06	6.66e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—SRC—sarcoma	6.3e-06	6.64e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—EGFR—sarcoma	6.3e-06	6.64e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—TP53—sarcoma	6.19e-06	6.53e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—VEGFA—sarcoma	6.13e-06	6.47e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IL2—sarcoma	6.1e-06	6.43e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—NRAS—sarcoma	6.06e-06	6.39e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MDM2—sarcoma	6.05e-06	6.38e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—KRAS—sarcoma	5.97e-06	6.29e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—KRAS—sarcoma	5.95e-06	6.27e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CCND1—sarcoma	5.95e-06	6.27e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—JUN—sarcoma	5.93e-06	6.26e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—HRAS—sarcoma	5.92e-06	6.24e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CTNNB1—sarcoma	5.89e-06	6.21e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MYC—sarcoma	5.64e-06	5.95e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PLCG1—sarcoma	5.54e-06	5.85e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—EGFR—sarcoma	5.52e-06	5.82e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IL2—sarcoma	5.41e-06	5.71e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—SRC—sarcoma	5.32e-06	5.61e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—TP53—sarcoma	5.3e-06	5.59e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—TP53—sarcoma	5.29e-06	5.58e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CCND1—sarcoma	5.27e-06	5.56e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—JUN—sarcoma	5.26e-06	5.55e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CTNNB1—sarcoma	5.22e-06	5.51e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—KRAS—sarcoma	5.22e-06	5.5e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—VEGFA—sarcoma	5.18e-06	5.47e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—NRAS—sarcoma	5.12e-06	5.4e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—HRAS—sarcoma	5.07e-06	5.35e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—HRAS—sarcoma	5.06e-06	5.33e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MYC—sarcoma	4.77e-06	5.03e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—SRC—sarcoma	4.72e-06	4.98e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—EGFR—sarcoma	4.67e-06	4.92e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—TP53—sarcoma	4.64e-06	4.89e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—VEGFA—sarcoma	4.6e-06	4.85e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—NRAS—sarcoma	4.54e-06	4.79e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—HRAS—sarcoma	4.43e-06	4.68e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—KRAS—sarcoma	4.41e-06	4.65e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MYC—sarcoma	4.23e-06	4.46e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—EGFR—sarcoma	4.14e-06	4.36e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—TP53—sarcoma	3.92e-06	4.13e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—KRAS—sarcoma	3.91e-06	4.12e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—HRAS—sarcoma	3.75e-06	3.95e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TP53—sarcoma	3.47e-06	3.66e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—HRAS—sarcoma	3.32e-06	3.5e-05	CbGpPWpGaD
